The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Platelet Glycoprotein IIb/IIIa Antagonists: What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use?
Open accessAbstract
Abstract—During the last decade, intensive efforts have been made to evaluate the role of the platelet glycoprotein (GP) IIb/IIIa complex in platelet-mediated thrombus formation. Significant efforts have also been made to design potent antagonists of this “final common pathway” of platelet aggregation to be used as novel therapeutic strategies to treat acute coronary syndromes. Although several different GP IIb/IIIa antagonists have convincingly demonstrated the usefulness of this platelet-directed therapeutic strategy, a number of lingering unsolved and sometimes misunderstood issues concerning the pharmacology and optimal clinical usefulness of these agents remain to be explored. This article reviews these issues, which include antagonist affinity, reversibility, and receptor specificity. Other issues are related to the effects of GP IIb/IIIa receptor availability, neoepitopes induced by antagonist binding with the potential to mediate thrombocytopenia, optimal methods of platelet monitoring and, perhaps ultimately, the potential therapeutic index of the oral class of GP IIb/IIIa antagonists. All of these specific issues are likely to be illuminated in the next several years, which will greatly determine the breadth of this therapeutic class.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Fuster, V (1994) · Circulation · doi:10.1161/01.cir.90.4.2126 · Cited by 848
Cited by
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Flavor Chemistry of Cocoa and Cocoa Products—An Overview
Aprotosoaie, A. C., Luca, S. V., & Miron, A. (2016) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12180 · Cited by 492
Metadata
- Authors
- Scarborough, R. M., Kleiman, N. S., & Phillips, D. R.
- Venue
- Circulation
- Published
- 1999-07-27
- Volume
- 100
- Issue
- 4
- Pages
- 437-444
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2160757156
- Cited by
- 246
- References
- 2
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet Glycoprotein IIb/IIIa Antagonists: What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? https://app.cochat.ai/papers/10.1161/01.cir.100.4.437
- The paper
- Scarborough, R. M., Kleiman, N. S., & Phillips, D. R. (1999). Platelet Glycoprotein IIb/IIIa Antagonists: What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation. https://doi.org/10.1161/01.cir.100.4.437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.